Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice

NCT03895463 · clinicaltrials.gov ↗

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Reassessment of study feasibility

Conditions

Neuroendocrine Tumors

Sponsor

Ipsen